Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
Jian Li(Guangdong University of Technology), Lin Shen(Peking University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunmei Shi(Fujian Medical University), Yaling Xu(Wuhan Sixth Hospital), Yunong Gao(Ministry of Education), Ye Xu(Fudan University Shanghai Cancer Center), Aimin Zang, Jing Wang(Qingdao University), Dong Wang(Chongqing University), Tianshu Liu(Sun Yat-sen University), Jianming Xu(Chinese People's Liberation Army), Yidi Wang(Nanjing Medical University), Cong Fei(New York University), Yi Huang(Hubei Cancer Hospital), Yanqiao Zhang(Harbin Medical University), Haiping Jiang(Zhejiang Chinese Medical University), Yanhong Deng(Sun Yat-sen University), Ying Yuan(Second Affiliated Hospital of Zhejiang University), Quanli Gao(Zhengzhou University)
Cited by 2
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657